{"id":"NCT01248780","sponsor":"Centocor, Inc.","briefTitle":"Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Golimumab in the Treatment of Chinese Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2011-10","completion":"2012-07","firstPosted":"2010-11-25","resultsPosted":"2013-07-01","lastUpdate":"2013-09-06"},"enrollment":264,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Golimumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Methotrexate (MTX)","otherNames":[]}],"arms":[{"label":"Golimumab + methotrexate (MTX)","type":"EXPERIMENTAL"},{"label":"Placebo + methotrexate (MTX)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese patients with rheumatoid arthritis.","primaryOutcome":{"measure":"American College of Rheumatology (ACR) 20 Response, Using CRP (C-reactive Protein), at Week 14","timeFrame":"Week 14","effectByArm":[{"arm":"Group I: Placebo + MTX","deltaMin":21,"sd":null},{"arm":"Group II: Golimumab 50 mg + MTX","deltaMin":54,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":9,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":128},"commonTop":["Upper Respiratory Tract Infection","Liver Function Test Abnormal","Anaemia"]}}